FDA Backtracks On Moderna mRNA Flu Vaccine Refusal, Sets Aug. 5 Review Deadline

By Maaisha Osman / February 18, 2026 at 2:32 PM

After facing a wave of backlash from regulated industry and public health stakeholders over its refusal to review Moderna’s mRNA vaccine candidate for influenza, FDA agreed following a Type A meeting with the company to review the vaccine and set an Aug. 5 goal date for a decision, backtracking on one of the most controversial vaccine policy moves from Vinay Prasad’s biologics center.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.